debrisoquin has been researched along with Metabolism, Inborn Errors in 8 studies
Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.
Metabolism, Inborn Errors: Errors in metabolic processes resulting from inborn genetic mutations that are inherited or acquired in utero.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Debrisoquine was a weak, noncompetitive inhibitor of alfentanil metabolism and of the formation of its major metabolites, with Ki values between 2." | 1.27 | Is the metabolism of alfentanil subject to debrisoquine polymorphism? A study using human liver microsomes. ( Hendrickx, JJ; Heykants, JJ; Lauwers, W; Lavrijsen, KL; Meuldermans, WE; Van Dyck, DM; Van Houdt, JM; Woestenborghs, RJ, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (87.50) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Roots, I | 1 |
| Dick, B | 1 |
| Küpfer, A | 1 |
| Molnàr, J | 1 |
| Braunschweig, S | 1 |
| Preisig, R | 1 |
| Danhof, M | 1 |
| Idle, JR | 3 |
| Teunissen, MW | 1 |
| Sloan, TP | 1 |
| Breimer, DD | 1 |
| Smith, RL | 2 |
| Mahgoub, A | 1 |
| Dring, LG | 1 |
| Lancaster, R | 1 |
| Du, YL | 1 |
| Lou, YQ | 1 |
| Vesell, ES | 1 |
| Lavrijsen, KL | 1 |
| Van Houdt, JM | 1 |
| Van Dyck, DM | 1 |
| Hendrickx, JJ | 1 |
| Woestenborghs, RJ | 1 |
| Lauwers, W | 1 |
| Meuldermans, WE | 1 |
| Heykants, JJ | 1 |
8 other studies available for debrisoquin and Metabolism, Inborn Errors
| Article | Year |
|---|---|
[Genetic causes for the variability of effects and side effects of drugs].
Topics: Debrisoquin; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hydroxylation; Kinetic | 1982 |
[Drug hydroxylation disorders (debrisoquin type) in a random sample of the Swiss population].
Topics: Adolescent; Adult; Aged; Debrisoquin; Female; Homozygote; Humans; Hydroxylation; Isoquinolines; Male | 1982 |
Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation.
Topics: Aging; Antipyrine; Body Weight; Debrisoquin; Female; Half-Life; Humans; Hydroxylation; Isoquinolines | 1981 |
Polymorphic hydroxylation of Debrisoquine in man.
Topics: Administration, Oral; Adolescent; Adult; Alleles; Biological Availability; Chemical Phenomena; Chemi | 1977 |
Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population.
Topics: Adolescent; Adult; Asian People; China; Debrisoquin; Female; Humans; Incidence; Isoquinolines; Male; | 1990 |
Poor metabolisers of debrisoquine reveal their true colours.
Topics: Alleles; Debrisoquin; Humans; Isoquinolines; Metabolism, Inborn Errors; Polymorphism, Restriction Fr | 1989 |
Pharmacogenetic approaches to the prediction of drug response.
Topics: Debrisoquin; Disease Susceptibility; Drug Hypersensitivity; Drug-Related Side Effects and Adverse Re | 1986 |
Is the metabolism of alfentanil subject to debrisoquine polymorphism? A study using human liver microsomes.
Topics: Alfentanil; Chromatography, High Pressure Liquid; Debrisoquin; Fentanyl; Humans; Hydroxylation; Isoq | 1988 |